Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NewBridge Pharmaceuticals logo — A regional specialty company providing a one-stop-solution t...

NewBridge Pharmaceuticals

A regional specialty company providing a one-stop-solution to the MENA region for USFDA/EMA approved products

Founded 2010 United Arab Emirates United Arab Emirates 252 employees Series C Total: $60.00M Biotechnology, Medical Devices +1

General Information

Company Name NewBridge Pharmaceuticals
Founded Year 2010
Location United Arab Emirates United Arab Emirates +1
Employees 252
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Series C
Social

Get notified when NewBridge Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About NewBridge Pharmaceuticals

NewBridge Pharmaceuticals is a regional specialty company based in the United Arab Emirates, specializing in providing a one-stop solution for USFDA/EMA approved products in the Middle East and Africa. Established in 2007, NewBridge aims to bridge the access gap and collaborate with pharmaceutical and biotech companies to in-license and commercialize innovative pharmaceutics, biologics, and other healthcare solutions in the region. The company's strategic focus areas include Oncology, Immunology, Neuroscience, Gastrointestinal & Nutrition. With a product portfolio addressing unmet medical needs, NewBridge has gained a substantial presence and facilitated patients' access to much-needed innovations. Its leadership team, experienced in the biopharmaceutical industry regionally and globally, has solidified NewBridge as a strategic pharmaceutical partner in the MENA region. NewBridge offers flexible partnership opportunities and best practices in commercial, regulatory, and medical affairs, focusing on quality performance and high standards of compliance. The company has secured a $48.00M Series C investment on 29 May 2013 from investors such as Burrill & Company, Elan Corporation, and Kuwait Life Sciences Company. This financial backing and life science network support NewBridge’s vision to create value through an innovative business approach and build successful alliances in the region. Its integrated strategy of regional expertise and strong global business network positions NewBridge as the preferred partner-of-choice for biopharmaceutical and healthcare companies seeking multi-country access in the Middle East and Africa.

Taxonomy: pharmaceuticals, biologics, oncology, immunology, neuroscience, gastrointestinal, nutrition, healthcare solutions, MENA region, commercialization, FDA approval, EMA approval, partnerships, regional expertise, institutional investors

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 3
Investor
•••• •••• 		29 May 2013
Series B •••••• 2
Investor
•••• •••• 		20 Sep 2010

NewBridge Pharmaceuticals Alternatives & Competitors

NewBridge Pharmaceuticals vs
MEAgate International FZ-LLC
MEAgate International FZ-LLC United Arab Emirates

MEAgate is the healthcare partner of choice for innovative multinational company to enter and commer...

7 employees
NewBridge Pharmaceuticals vs
Genpharm
Genpharm United Arab Emirates

The leading partner of choice for Rare Disease market access in the MENA Region. Commit . Connect ....

98 employees
Health Care, Marketing

FAQ About NewBridge Pharmaceuticals

A regional specialty company providing a one-stop-solution to the MENA region for USFDA/EMA approved products
NewBridge Pharmaceuticals was founded in 2010.
NewBridge Pharmaceuticals is headquartered in United Arab Emirates.
NewBridge Pharmaceuticals operates in the following industries: Biotechnology, Medical Devices, Pharmaceutical.
NewBridge Pharmaceuticals has approximately 252 employees.
NewBridge Pharmaceuticals has completed 2 funding rounds, raising a total of $60.00M. The latest funding stage is Series C.
Top alternatives and competitors to NewBridge Pharmaceuticals include MEAgate International FZ-LLC, Genpharm. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NewBridge Pharmaceuticals and MEAgate International FZ-LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors NewBridge Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy